RashmiKanagal ShamannaMDFCAP(She/Her)

Summary

• Dr. Rashmi Kanagal-Shamanna is a practicing triple board-certified Molecular Genetic Pathologist and Hematopathologist at The University of Texas MD Anderson Cancer Center. She is a tenured Professor and co-director of the clinical Bone Marrow Laboratory, and Molecular Diagnostic Laboratory (Innovative Diagnostics section). Dr. Kanagal-Shamanna received her MD from St. John’s Medical College, Bangalore, India followed by a residency in Anatomic & Clinical Pathology at Henry Ford Hospital, Detroit, Michigan. She completed her fellowships in Hematopathology, Advanced Hematopathology, & Molecular Genetic Pathology at M.D. Anderson Cancer Center. Dr. Kanagal-Shamanna’s clinical responsibilities include the development and validation of genomic assays and clinical reporting, signing out bone marrow and lymph node biopsies among others. Her primary research interest is the application of novel tools for molecular profiling of hematological malignancies for prognosis and guiding therapy. Dr. Kanagal has >250 highly cited peer-reviewed publications in her field. She is the recipient of the Leukemia SPORE career development award, Ladies Leukemia League grant, and RPF award. Dr. Kanagal is an invited lead author for the 2022 World Health Organization (WHO) Classification of Hematolymphoid Tumors, and author of the WHO Genetic Tumor Syndromes. Her work on myeloid neoplasms with isochromosome (17q) has led to its recognition as a provisional entity in the International Consensus Classification (ICC) system. Dr. Kanagal-Shamanna is on the Board of Directors for the Cancer Genomics Consortium, where she also served as the President (2023-2024). She co-leads the Clinical Genome (ClinGen) resource’s Somatic Hematologic Malignancy Taskforce. She is the past chair of the Professional Association Collaboration Committee tasked with developing guidelines for the appropriate utilization of genomic assays in patient care. She serves on the editorial board of Cancer Genetics.